GlassScriptPhysician profile
Aristides A Sastre
NPI 1689818494
$3,904.09
in general payments reported to CMS, 2019-2025
33 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $267 · 2022: $27.09 · 2023: $496 · 2024: $1,143 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.11 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $538.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $352.51 | 2023-2025 | |
| Amgen INC. | $314.69 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $302.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $272.61 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $166.05 | 2023-2025 | Synthroid, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.28 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $100.46 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $100.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.01 | 2023-2024 | |
| Antares Pharma, INC. | $92.64 | 2024-2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.08 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $80.31 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $78.44 | 2020-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.79 | 2019-2025 | Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $70.81 | 2019-2020 | |
| Dynavax Technologies Corporation | $61.83 | 2023-2025 | Heplisav-B |
| Shield Therapeutics INC | $58.10 | 2025 | |
| Radius Health, INC. | $56.23 | 2025 | |
| Vivus LLC | $31.13 | 2019-2023 | Qsymia |
| Phathom Pharmaceuticals, INC. | $27.54 | 2024 | Voquezna |
| Coloplast Corp | $26.79 | 2020 | |
| Daiichi Sankyo INC. | $24.10 | 2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $23.79 | 2019 | |
| Astellas Pharma US INC | $19.81 | 2024 | Veozah |
| Sanofi Pasteur INC. | $19.50 | 2023 | |
| Mannkind Corporation | $15.16 | 2020 | |
| Metuchen Pharmaceuticals | $14.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.28 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.11 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aristides Sastre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.